Conflict-of-interest disclosure: S.C.M. reports grants from University of Cologne (KoelnFortune), Dr Manfred Plempel Stipend, German Center for Infection Research (DZIF) clinical leave, and personal fees from Octapharma, outside the submitted work. O.A.C. reports grants and contracts from Amplyx, Basilea, the Federal Ministry of Education and Research, Cidara, DZIF, the Directorate-General for Research and Innovation (101037867), The Rare Fungal Disease Company, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, and Scynexis; consulting fees from AbbVie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, Mycoses Study Group Education & Research Consortium (MSG-ERC), Noxxon, Octapharma, Pardes, Pfizer, Scynexis, and Seres; honoraria for lectures from Abbott, AbbVie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, MSD, Mylan, Noscendo, Pfizer, and Shionogi; payment for expert testimony from Cidara; participation in a data safety monitoring board or an advisory board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, Pulmocide, Shionogi, and The Prime Meridian Group; a patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); stocks from CoRe Consulting; and other interests from the German Society for Haematology and Medical Oncology, Deutsche Gesellschaft für Infektiologie, the European Confederation of Medical Mycology, the International Society for Human and Animal Mycology, MSG-ERC, and Wiley, outside the submitted work.